辅助奥拉帕尼是所有高危her2阴性早期乳腺癌的标准治疗吗？

{"title":"辅助奥拉帕尼是所有高危her2阴性早期乳腺癌的标准治疗吗？","authors":"Pierre Foidart, Guy Jerusalem","doi":"10.21037/gs-24-467","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 2","pages":"257-262"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921398/pdf/","citationCount":"0","resultStr":"{\"title\":\"Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer presenting <i>gBRCA1/2</i> mutations?\",\"authors\":\"Pierre Foidart, Guy Jerusalem\",\"doi\":\"10.21037/gs-24-467\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12760,\"journal\":{\"name\":\"Gland surgery\",\"volume\":\"14 2\",\"pages\":\"257-262\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921398/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gland surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/gs-24-467\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gland surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/gs-24-467","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}